There have been considerable changes to the format of the recommendations since the previous version (version 7). The majority of the footnotes to the tables have been removed and the notations added to the end column; it is hoped that this change will avoid confusion in interpretation. Antibiotics have been separated into groups, e.g. b-lactams, aminoglycosides, etc. Recommendations for urinary tract infections (UTIs) have been removed for most agents except for those that are administered solely for the treatment of uncomplicated UTIs or where there are limited recommendations for specific organisms, e.g. trimethoprim. For agents that previously had dual recommendations, systemic recommendations remain and the intermediate category can be used for interpretation for UTIs because intermediate susceptibility infers that the infection may respond as the agent is concentrated at the site of infection. This change will also avoid errors in interpretation when an organism is isolated from multiple sites, e.g. blood and urine. The changes that have been made to version 7 are as follows: MIC and zone diameter breakpoints (BPs) for trimethoprim, fosfomycin and nitrofurantoin for UTIs (Table 7) ; MIC and zone diameter breakpoints (BPs) for doripenem (Tables 7-9); colistin MIC BPs for Pseudomonas spp. (Table 9 ), co-trimoxazole MIC BPs for Stenotrophomonas maltophilia (Table 10) ; staphylococci MIC and zone diameter BPs for clarithromycin, clindamycin, erythromycin, quinupristin/ dalfopristin, trimethoprim UTI, nitrofurantoin UTI and rifampicin (Table 11) ; Streptococcus pneumoniae MIC and zone diameter BPs for azithromycin, clarithromycin, erythromycin, co-trimoxazole, linezolid, rifampicin and telithromycin (Table 12) ; addition of streptomycin recommendations for enterococci (Table 13) ; enterococcal MIC and zone diameter BPs for quinupristin/dalfopristin, nitrofurantoin UTI and trimethoprim UTI (Table 13) ; b-haemolytic streptococci MIC and zone diameter BPs for azithromycin, clarithromycin, erythromycin and telithromycin (Table 15) ; clarithromycin and erythromycin MIC and zone diameter BPs for Moraxella catarrhalis (Table 16) ; azithromycin MIC BPs for Neisseria gonorrhoeae (Table 17) ; chloramphenicol and rifampicin MIC BPs for Neisseria meningitidis (Table 18) ; azithromycin MIC BPs for Haemophilus influenzae (Table 19) ; MIC BPs for metronidazole for Bacteroides fragilis, Bacteroides thetaiotaomicron and Clostridium perfringens (Tables 23-25 , respectively); susceptibility testing of Listeria spp. (Appendix 3); the acceptable range for ATCC 25923 to a 10 mg tobramycin disc (Table 26) .
Introduction
The BSAC Guide to Sensitivity Testing was first published in 1991 and one of its most important sections was that dealing with breakpoints for clinically relevant bacteria. 1 These breakpoints have been used extensively to interpret MIC results and for single concentration 'breakpoint' tests. However, a criticism of the guidelines was that they did not provide a standardized method of disc diffusion testing with zone limits that correlated with these MIC breakpoints. The limitations of the widely used Stokes' comparative method were also a cause for concern.
The task of developing such a method of disc testing is immense and the Working Party and the Council of the BSAC needed evidence that there was sufficient interest to warrant the investment required not only in the short term, but also for continuing support and development. This necessary confirmation was obtained from a questionnaire survey, 2 which indicated that 90.6% of UK laboratories would be prepared to switch to an upgraded disc test, and the development and 'field testing' of the standardized method were therefore undertaken. 3 Fortuitously, the introduction of the standardized method has coincided with the availability of automated zone measuring devices, which aid measuring and interpretation considerably. With laboratories using the same method there is a real opportunity to combine zone diameter data, so that levels of resistance in the UK and Ireland can be surveyed, and subtle changes in susceptibility detected.
The method, like all standardized disc tests, cannot be adapted by the user, with the exception that various methods of inoculum preparation can be used to achieve semi-confluent growth.
For microorganisms not included in this document, work is either ongoing (e.g. anaerobes) or reported elsewhere (e.g. mycobacteria). 4 1 Preparation of plates 1.1 Prepare Iso-Sensitest agar (ISA; Oxoid, Basingstoke, UK), or media shown to have the same performance as ISA, according to the manufacturer's instructions. Supplement media for fastidious organisms with 5% defibrinated horse blood or 5% defibrinated horse blood and 20 mg/L b-nicotinamide adenine dinucleotide (NAD) as indicated in Table 1 . Use Columbia agar with 2% NaCl for methicillin/oxacillin susceptibility testing of staphylococci. 1.2 Pour sufficient molten agar into sterile Petri dishes to give a depth of 4+0.5 mm (25 mL in a 90 mm Petri dish).
1.3 Dry the surface of the agar to remove excess moisture before use. The length of time needed to dry the surface of the agar depends on the drying conditions, e.g. whether a fan-assisted drying cabinet or 'still air' incubator is used, whether plates are dried before storage and storage conditions. It is important that plates are not over-dried. 1.4 Store the plates in vented plastic boxes at 8 -108C prior to use. Alternatively the plates may be stored at 4 -88C in sealed plastic bags. Plate drying, method of storage and storage time should be determined by individual laboratories as part of their quality assurance programme. In particular, quality control tests should confirm that excess surface moisture is not produced and that plates are not over-dried.
Selection of control organisms
2. 1 The performance of the tests should be monitored by the use of appropriate control strains. The control strains listed (Tables 2 and 3 ) include susceptible strains that have been chosen to monitor test performance and resistant strains that can be used to confirm that the method will detect phenotypically resistant isolates. 2.2 Store control strains at 2708C on beads in glycerol broth. Non-fastidious organisms may be stored at 2208C. Two vials of each control strain should be stored, one for an 'in-use' supply, the other for archiving. 2.3 Every week subculture a bead from the 'in-use' vial on to appropriate non-selective media and check for purity. From this pure culture, prepare one subculture on each of the following b ISA supplemented with 5% defibrinated horse bloodþ20 mg/L NAD may be used for testing.
5 days. For fastidious organisms that will not survive on plates for 5/6 days, subculture the strain daily for no more than 6 days.
Preparation of inoculum
The inoculum should give semi-confluent growth of colonies after overnight incubation. Use of an inoculum that yields semi-confluent growth has the advantage that an incorrect inoculum can easily be observed. A denser inoculum will result in reduced zones of inhibition and a lighter inoculum will have the opposite effect. The following methods reliably give semiconfluent growth with most isolates. NB. Other methods of obtaining semi-confluent growth may be used if they are shown to be equivalent to the following. Table 3 . Control strains with a resistance mechanism that can be used to confirm that the method will detect resistance The information in bold is tentative. Breakpoints will remain tentative for 1 year from when published. Comments a-f relate to urinary tract infections (UTIs) only. a UTI recommendations are for organisms associated with uncomplicated urinary infections only. For complicated UTI systemic recommendations should be used. b If an organism is isolated from multiple sites, e.g. from blood and urine, interpretation of susceptibility should be made with regard to the systemic site (e.g. if the blood isolate is resistant and the urine isolate susceptible, both should be reported resistant irrespective of the results obtained using interpretative criteria for urine isolates). c For agents not listed, criteria given for systemic isolates may be used for urinary tract isolates. Intermediate susceptibility infers that the infection may respond as the agent is concentrated at the site of infection. d Direct susceptibility tests on urine samples may be interpreted only if the inoculum gives semi-confluent growth. e In the absence of definitive organism identification, use the recommendations most appropriate for the presumptive identification, accepting that on some occasions the interpretation may be incorrect. A more cautious approach is to use the systemic recommendations. 
Dilution of suspension adjusted to the turbidity of a 0.5 McFarland standard
See Table 4 for details. These suspensions should be used within 15 min of preparation.
Photometric standardization of turbidity of suspensions
A photometric method of preparing inocula was described by Moosdeen et al. 6 and from this the following simplified procedure has been developed.
3.3.1 Suspend colonies (touch four or five when possible) in 3 mL of distilled water or broth in a 100Â12 mm glass tube (note that tubes are not reused) to give turbidity that is just visible. Do not leave the organisms standing in water. It is essential to get an even suspension. 3.3.2 Zero the spectrophotometer with a sterile water or broth blank (as appropriate) at a wavelength of 500 nm. Measure the optical density of the bacterial suspension. (The spectrophotometer must have a cellholder for 100Â12 mm test tubes. A much simpler photometer would also probably be acceptable. The 100Â12 mm test tubes could also be replaced with another tube/cuvette system if required, but the dilutions would need to be recalibrated.) 3.3.3 From Table 5 select the volume to transfer (with the appropriate fixed volume micropipette) to 5 mL of sterile distilled water. (As different spectrophotometers may differ slightly, it may be necessary to adjust the dilutions slightly to achieve semi-confluent growth with any individual set of laboratory conditions.)
Direct susceptibility testing
The Working Party does not advocate direct susceptibility testing, as the control of inoculum is impossible. However, we are aware that this is a common practice in many laboratories and therefore we are suggesting methods that will achieve the correct inoculum size for a reasonable proportion of infected urines. The following methods have been developed and recommended by laboratories that use the BSAC method and we suggest adopting whichever method best suits individual laboratory working practice. If the inoculum is not correct and growth is not semi-confluent, or the culture is mixed, the test must be repeated. The information in bold is tentative. Breakpoints will remain tentative for 1 year from when first published. The information in bold is tentative. Breakpoints will remain tentative for 1 year from when first published.
Direct susceptibility testing of urines
(i) Method 1: thoroughly mix the urine, place a 10 mL loop of urine in the centre of the susceptibility plate and spread with a dry swab. (ii) Method 2: thoroughly mix the urine, then dip a sterile cotton-wool swab in the urine and remove excess. Make a cross in the centre of the susceptibility plate then spread with a sterile dry swab. If only small numbers of organisms are seen under the microscope, the initial cotton-wool swab may be used to inoculate and spread the susceptibility plate. 
Inoculation of agar plates
4.1 Use the adjusted suspension within 15 min to inoculate plates by dipping a sterile cotton-wool swab into the suspension and remove the excess liquid by turning the swab against the side of the container. Spread the inoculum evenly over the entire surface of the plate by swabbing in three directions. Allow the plate to dry before applying discs. Note that if inoculated plates are left at room temperature for extended times before the discs are applied the organism may begin to grow, resulting in reduced zones of inhibition. Discs should therefore be applied to the surface of the agar within 15 min of inoculation.
Use of rotary platers for susceptibility testing
Rotary platers can be used for inoculating susceptibility tests but care must be taken. The swab must be moved at an even pace to ensure that the inoculum is semi-confluent and that no gaps are present between the swab streaks.
5 Antimicrobial discs
Disc contents
Disc contents are given in Tables 7 -30.   Table 10 . The MIC breakpoint is based on the trimethoprim concentration in a 1:19 combination with sulfamethoxazole. The MIC breakpoint has changed but a review of the data indicates that no adjustment of the zone diameter breakpoints is necessary.
The information in bold is tentative. Breakpoints will remain tentative for 1 year from when first published. The information in bold is tentative. Breakpoints will remain tentative for 1 year from when first published. Comments a-c relate to urinary tract infections (UTIs) only. a These recommendations are for organisms associated with uncomplicated UTIs only. For complicated infections and infections caused by Staphylococcus aureus and Staphylococcus epidermidis, which are associated with more serious infections, systemic recommendations should be used. b If an organism is isolated from multiple sites, e.g. from blood and urine, interpretation of susceptibility should be made with regard to the systemic site (e.g. if the blood isolate is resistant and the urine isolate susceptible, both should be reported resistant irrespective of the results obtained using interpretative criteria for urine isolates). c Direct susceptibility tests on urine samples may be interpreted only if the inoculum gives semi-confluent growth. The information in bold is tentative. Breakpoints will remain tentative for 1 year from when first published. The information in bold is tentative. Breakpoints will remain tentative for 1 year from when first published. Comments a-c relate to urinary tract infections (UTIs) only. a UTI recommendations are for organisms associated with uncomplicated urinary tract infections only. For complicated urinary tract infections and infections systemic recommendations should be used. b If an organism is isolated from multiple sites, e.g. from blood and urine, interpretation of susceptibility should be made with regard to the systemic site (e.g. if the blood isolate is resistant and the urine isolate susceptible, both should be reported resistant irrespective of the results obtained using interpretative criteria for urine isolates). c Direct susceptibility tests on urine samples may be interpreted only if the inoculum gives semi-confluent growth. The information in bold is tentative. Breakpoints will remain tentative for 1 year from when first published. that are resistant to ciprofloxacin yet susceptible to nalidixic acid in disc diffusion tests. The mechanism of resistance and the prevalence of these isolates in the UK is still under investigation.
Isolates with reduced susceptibility to fluoroquinolones normally have no zone of inhibition with a 30 mg nalidixic acid disc. For organisms with nalidixic acid zone diameters 10-31 mm a ciprofloxacin MIC should be determined if the patient is to be treated with this agent. Nalidixic acid ---30 9 10 -31 32
Miscellaneous antibiotics Azithromycin 0.5 0.5 0.25 15 27 -28 Zone diameter breakpoints relate to the MIC breakpoint of .0.5 mg/L as disc diffusion testing will not reliably differentiate between the intermediate and susceptible populations. Erythromycin 0.5 0.5 5 11 -12 Erythromycin is no longer used for therapy, but may be tested for epidemiological purposes. Rifampicin  1  -1  2  20 -21  Spectinomycin 64  -64  25  13 -14  Tetracycline  1  -1  10 26 -27 The tetracycline result may be used to infer susceptibility to doxycycline.
The information in bold is tentative. Breakpoints will remain tentative for 1 year from when first published. The information in bold is tentative. Breakpoints will remain tentative for 1 year from when first published. 
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Storage and handling of discs
Loss of potency from discs will result in reduced zones of inhibition. To avoid loss of potency as a result of improper handling the following procedures are essential. 
Application of discs
Discs should be firmly applied to the surface of an agar plate that has been dried previously. The contact with the agar should be even. A 90 mm plate will accommodate six discs without unacceptable overlapping of zones.
Incubation
Timing
If the plates are left at room temperature after discs have been applied, larger zones of inhibition may be obtained compared with zones produced when plates are incubated immediately. Plates therefore should be incubated within 15 min of disc application.
Conditions of incubation
Conditions of incubation for different organisms are summarized in Table 6 . Stacking plates too high in the incubator may affect results owing to uneven heating of plates. The efficiency of heating of plates depends on the incubator and the racking system used. Control of incubation, including height of plate stacking, should therefore be part of the laboratory's quality assurance programme.
7 Measuring zones and interpretation
Acceptable inoculum density
The inoculum should give semi-confluent growth of colonies on the susceptibility plate, within the range illustrated in Figure 1 .
Measuring zones
7.2.1 Measure the diameters of zones of inhibition to the nearest millimetre (zone edge should be taken as the point of Table 22 . There is no evidence to change the epidemiological zone diameter breakpoint with the change in MIC breakpoint.
The information in bold is tentative. Breakpoints will remain tentative for 1 year from when first published. 
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Breakpoints for testing susceptibility to co-trimoxazole are provided. However, the following recommendations from the UK Committee on the Safety of Medicines (CSM) should be noted. 'Co-trimoxazole should be limited to the role of drug of choice in Pneumocystis carinii pneumonia; it is also indicated for toxoplasmosis and nocardiasis. It should now only be considered for use in acute exacerbations of chronic bronchitis and infections of the urinary tract when there is good bacteriological evidence of sensitivity to co-trimoxazole and good reason to prefer this combination to a single antibiotic; similarly it should only be used in acute otitis media in children when there is good reason to prefer it. Review of the safety of co-trimoxazole using spontaneous adverse drug reaction data has indicated that the profile of reported adverse reactions with trimethoprim is similar to that with co-trimoxazole; blood and generalized skin disorders are the most serious reactions with both drugs and Lightest acceptable Ideal Heaviest acceptable Figure 1 . Acceptable inoculum density range for a Gram-negative bacillus.
Obvious zone edge to be measured
Inner zone NOT to be measured Examine this area for minute colonies predominantly have been reported to occur in elderly patients. A recent large post-marketing study has demonstrated that such reactions are very rare with co-trimoxazole; the study did not distinguish between co-trimoxazole and trimethoprim with respect to serious hepatic, renal, blood or skin disorders.' Appendix 2. Efficacy of cefaclor in the treatment of respiratory infections caused by H. influenzae
Concerns have been expressed, particularly by laboratories moving from Stokes' method to the BSAC disc diffusion method, about the interpretation of susceptibility of H. influenzae to cefaclor. When using Stokes' method the majority of isolates appeared susceptible; but with the BSAC disc diffusion method most isolates are now reported resistant. The following comments explain the BSAC rationale for interpretation of cefaclor susceptibility.
Cefaclor pharmacokinetics
Cefaclor is dosed at 250-500 mg orally three times daily: 250 mg three times daily is probably the most common dose but data to confirm this are absent. The expected C max for 250 mg is 5 -10 mg/L and 10-20 mg/L for 500 mg; the half-life is 1 h; drug concentration in blood is ,1 mg/L at 4 h and protein binding is 25-50%. Tissue penetration is similar to other b-lactams.
Cefaclor potency against H. influenzae 
Pharmacodynamics
An average patient with an H. influenzae infection will have a free drug time .MIC of 25% with 250 mg dosing and 37% with 500 mg dosing. A conservative time .MIC target for cephalosporins in community practice is 40% -50%, but this is not achieved with cefaclor. Therefore, it is likely that cefaclor will have at best borderline activity against H. influenzae.
Conclusion
The pharmacodynamic data indicate that cefaclor has borderline activity against H. influenzae, even for community use. The outcome of infection will be difficult to predict and susceptibility testing is likely to be of limited value.
Appendix 3.
Susceptibility testing of Helicobacter pylori
Disc diffusion methods are not suitable for testing H. pylori as this species is slow growing and results may not be accurate. The recommended method of susceptibility testing is Etest (follow technical guide instructions). Suspend colonies from a 2-3 day culture on a blood agar plate in sterile distilled water and adjust the density to equal a McFarland 3 standard.
Use a swab dipped in the suspension to inoculate evenly the entire surface of the plate. The medium of choice is MuellerHinton agar or Wilkins -Chalgren agar with 5%-10% horse blood.
Allow the plate to dry and apply the Etest strip. Incubate at 358C in microaerophilic conditions for 3 -5 days.
Read the MIC at the point of complete inhibition of all growth, including hazes and isolated colonies. Tentative interpretative criteria for MICs are given in Table A1 . 
